We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: Hemispherx Must Complete At Least One More Ampligen Trial
FDA: Hemispherx Must Complete At Least One More Ampligen Trial
February 8, 2013
The FDA has issued a complete response letter (CRL) for Hemispherx Biopharma’s chronic fatigue syndrome (CFS) drug Ampligen, requesting at least one more clinical trial, various nonclinical studies and a number of data analyses.